1. Home
  2. BLMN vs ABUS Comparison

BLMN vs ABUS Comparison

Compare BLMN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLMN
  • ABUS
  • Stock Information
  • Founded
  • BLMN 1988
  • ABUS 2005
  • Country
  • BLMN United States
  • ABUS United States
  • Employees
  • BLMN N/A
  • ABUS N/A
  • Industry
  • BLMN Restaurants
  • ABUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLMN Consumer Discretionary
  • ABUS Health Care
  • Exchange
  • BLMN Nasdaq
  • ABUS Nasdaq
  • Market Cap
  • BLMN 595.5M
  • ABUS 611.0M
  • IPO Year
  • BLMN 2012
  • ABUS N/A
  • Fundamental
  • Price
  • BLMN $7.30
  • ABUS $3.71
  • Analyst Decision
  • BLMN Hold
  • ABUS Strong Buy
  • Analyst Count
  • BLMN 9
  • ABUS 3
  • Target Price
  • BLMN $9.25
  • ABUS $5.67
  • AVG Volume (30 Days)
  • BLMN 3.4M
  • ABUS 796.8K
  • Earning Date
  • BLMN 08-06-2025
  • ABUS 08-06-2025
  • Dividend Yield
  • BLMN 8.16%
  • ABUS N/A
  • EPS Growth
  • BLMN N/A
  • ABUS N/A
  • EPS
  • BLMN N/A
  • ABUS N/A
  • Revenue
  • BLMN $3,933,993,000.00
  • ABUS $15,416,000.00
  • Revenue This Year
  • BLMN $1.38
  • ABUS $138.02
  • Revenue Next Year
  • BLMN $1.52
  • ABUS N/A
  • P/E Ratio
  • BLMN N/A
  • ABUS N/A
  • Revenue Growth
  • BLMN 2.47
  • ABUS 53.23
  • 52 Week Low
  • BLMN $6.09
  • ABUS $2.71
  • 52 Week High
  • BLMN $17.89
  • ABUS $4.73
  • Technical
  • Relative Strength Index (RSI)
  • BLMN 44.28
  • ABUS 70.70
  • Support Level
  • BLMN $7.06
  • ABUS $3.60
  • Resistance Level
  • BLMN $7.40
  • ABUS $3.71
  • Average True Range (ATR)
  • BLMN 0.34
  • ABUS 0.11
  • MACD
  • BLMN 0.09
  • ABUS 0.02
  • Stochastic Oscillator
  • BLMN 82.30
  • ABUS 95.24

About BLMN Bloomin' Brands Inc.

Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabbas. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S. while restaurants operating outside the U.S. are included in the international segment.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: